TOP > 外国特許検索 > METHOD FOR PREDICTING PROGRESSION OF PRE-CANCEROUS LESION

METHOD FOR PREDICTING PROGRESSION OF PRE-CANCEROUS LESION

外国特許コード F150008592
整理番号 (S2014-0453-N0)
掲載日 2015年11月26日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2015JP053041
国際公開番号 WO 2015119132
国際出願日 平成27年2月4日(2015.2.4)
国際公開日 平成27年8月13日(2015.8.13)
優先権データ
  • 特願2014-019201 (2014.2.4) JP
発明の名称 (英語) METHOD FOR PREDICTING PROGRESSION OF PRE-CANCEROUS LESION
発明の概要(英語) Disclosed is a novel means for predicting whether or not a pre-cancerous lesion of cancer such as uterine cervical cancer would be exacerbated in future. A method for predicting the progression of a pre-cancerous lesion according to the present invention comprises determining the expression of aPKCλ/τ protein in a sample separated from a subject. It is predicted that the possibility of the exacerbation of the pre-cancerous lesion is high or the possibility of the amelioration of the pre-cancerous lesion is low when the expression amount of aPKCλ/τ protein is high and/or when aPKCλ/τ protein is localized in the nucleus. It is preferred that the analysis of the expression of aPKCλ/τ protein is performed by immunostaining using an anti-aPKCλ/τ antibody or an antigen-binding fragment thereof.
従来技術、競合技術の概要(英語) BACKGROUND ART
And the cervical intraepithelial neoplasia (Cervical Intraepithelial Neoplasia, CIN), generated in the cervical epithelium in cancer precursor lesion. Histopathology diagnosis of CIN stained with HE (hematoxylin - eosin staining) and performed, degree of modification is minor form is close to the normal epithelial CIN1, close to an invasive cancer in the form of a larger profile CIN3, 3 of the intermediate degree of modification of the classification stage CIN2.
Human papillomavirus (HPV) CIN and cervical cancer is the cause. However, HPV infection is needed (the occurrence of the CIN) rats but is not sufficient. Of women who are infected with HPV, to progress to invasive cancer of the cervix is, only one person in about 1000 1. HPV oncogenic of the infected, are naturally eliminated in many cases. Persistence of the infection in part, in a case where a pre-cancerous lesion proceeds to, and develop CIN does not proceed in some cases the necessity of cancer.
Uterine cancer examination and the like in the case where the high risk is determined, a diagnosis by biopsy. In the case where the biopsy the lesion is not found a number of returns to the normal cancer screening, diagnosis and the case CIN3 and the accommodation of the surgery. CIN1 Or CIN2 in the case of diagnosis and follow-up, again after a few months as required is performed to assess the progress of the lesion biopsy. CIN2 Is the long-term persistence of the state of the adaptive and surgery. Is a cervical surgery and removal of the cone, is to preserve the uterus, cervix of the post-operative restenosis, hemorrhage, post-operative complications such as increased rates of premature birth can occur.
The grade of the CIN and invasive cancer progression by cases that case, since it may return to normal with the necessity, and sort the risk of risk of each case sets the treatment contents corresponding to the ideal. Indeed, it is assumed that the diagnostic method (cervical tissue-eosin staining (HE) in the pathological diagnosis) is, but can be categorized according to the grade CIN, CIN grade cases for the same lesion in the case where there is a case where the necessity of future exacerbations, HE staining it cannot be predicted.
Therefore, the grade of the CIN far to predict exacerbations or the necessity of auxiliary diagnosis method has been developed. Up to the present method is used to put into practical use, the occurrence and progression of cervical squamous intraepithelial lesions is associated with HPV can be used to, taken from the body fluids or tissues from the cervix of a method for detecting HPV infection (Roche, Diagnostics Inc., trade name: AMPLICORE HPV; sekisui Medical Inc., trade name: Clinichip; QIAGEN Inc., trade name: such as Hybrid Capture II) and, the over-expression of HPV E7 protein in response to a method for detecting the p16 protein (Roche Inc., trade name: in the CINtec p16 Histology). However, associated with the progression of HPV as well as auxiliary diagnosis accuracy is not sufficient to be predicted.
On the other hand, is an atypical Protein Kinase C λ / ι (aPKC λ / ι), which controls the polarity of the cell and a protein, normal tissue has an important role in establishing and maintaining the form of a play. Cancer cell polarity and one of the features of the abnormality, an abnormality in the expression of various cancer aPKC λ / ι been reported. For cervical cancer, up to this point, the localization of the aPKC λ / ι in cancer invasion and poor prognosis expression abnormality be an abnormality have been reported (Non-Patent Document 1).
However, including cervical cancer, cancer of the precursor in a state in which the kinetics of the aPKC λ / ι is not reported so far, in a cancerous lesion before pathological significance aPKC λ / ι is not known.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY
  • 発明者(英語)
  • OHNO, Shigeo
  • MIZUSHIMA, Taichi
  • HIRAHARA, Fumiki
  • MIYAGI, Etsuko
  • SATO, Mikiko
  • NAKAYA, Masaaki
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
※ ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close